visiongain - Pharma - Upcoming Conferences

4th Annual Pharmaceutical PLM

info@visiongain.com (visiongain) — Tue, 14 Sep 2010 00:00:00 GMT

14th - 15th September 2010, Thistle Marble Arch, London, UK
Pharmaceutical and biopharmaceutical companies are under severe pressure to improve product pipelines, accelerate time to market, and improve margins on existing product, while maintaining strict adherence to quality principles and regulatory requirements. It is imperative that pharmaceutical and biotech companies address these business challenges to stay competitive, increase revenue, enhance profit, and reduce the risk of noncompliance.

CNS Clinical Trials

info@visiongain.com (visiongain) — Thu, 16 Sep 2010 00:00:00 GMT

16th - 17th September 2010, Thistle Marble Arch, London, UK
CNS is one of the largest and fastest growing therapeutic areas of the pharmaceutical market. The ageing of the baby-boom generation combined with new and emerging treatments for neurodegenerative disorders, including multiple sclerosis, Alzheimer's disease and Parkinson's disease, will lead to further expansion of the neurodegenerative therapies market.

Cell-Based Assays

info@visiongain.com (visiongain) — Mon, 20 Sep 2010 00:00:00 GMT

20th - 22nd September 2010, Hilton London Olympia, London, UK
Despite spiralling R&D costs, 90% of lead candidates identified by current in vitro systems fail to become drugs. Complications including cardiac, neural and hepato-toxicity remain significant challenges, frequently undetected in animal and pre-clinical testing.

9th Annual Pricing and Reimbursement

info@visiongain.com (visiongain) — Tue, 28 Sep 2010 00:00:00 GMT

28th - 29th September 2010, Bonhill House, London, UK
The rancorous debate in the United States over the healthcare reform has finally come to an end with passing of the landmark healthcare bill. It aims to lower the overall cost of healthcare and increase the quality of healthcare for all US citizens. Healthcare payers in all markets continue to endeavor pricing pressure on pharmaceutical companies to reduce costs. Bringing you the latest updates in pharmaceutical pricing and reimbursement, leading experts from Europe and the US, will present the best approaches for market access, and reveal most effective pricing strategies.

7th Annual Biosimilars Conference

info@visiongain.com (visiongain) — Tue, 05 Oct 2010 00:00:00 GMT

5th - 7th October 2010, BSG Conference Centre, London, UK
Biosimilars, biobetters and follow-on biologics are the new wave of growth for the pharmaceutical industry. According to the GIA report, the market for biosimilars in the US, Europe, and Japan is projected to exceed US$2 billion by 2015. As numerous countries including the United Status and EU collaborate, there exists a huge challenge in developing biosimilars across regulated and unregulated markets.

7th Annual Pain Management

info@visiongain.com (visiongain) — Mon, 18 Oct 2010 00:00:00 GMT

18th - 19th October 2010, BSG House, London, UK
Extensive availability of generic drugs, pipeline products and increasing demand for efficient medical devices has accelerated growth of the global pain management marketplace. However recent issues involving patent expiries of top NSAID's drugs, regulatory approvals and safety of analgesics classes are posing a huge challenge to this sector. How rapid will the pain management market grow in the next 10 years? What are the evolving segments of pain management and which new drugs in the pipeline will take the leap?

3rd Pre-filled Syringes

info@visiongain.com (visiongain) — Mon, 25 Oct 2010 00:00:00 GMT

25th - 27th October 2010, BSG Conference Centre, London, UK
Pre-filled syringe and injection devices are now the primary methods for parenteral drug delivery, ranging from oncology to autoimmune diseases. Soaring annual growth rates topping 10% will continue due to the need for greater safety and increased convenience from pre-fillable devices. However, challenges and threats continue to bedevil manufacturers, including lubrication and drug solution interaction and compatibility and bioavailability issues.

Anti-Counterfeiting Americas

info@visiongain.com (visiongain) — Mon, 08 Nov 2010 00:00:00 GMT

8th - 9th November 2010, Boston, USA
Increasing efforts are being made to protect the national supply chain for medicines distribution. In the US, the pharmaceutical supply chain involves the daily delivery of approximately 13 million prescription products to pharmacies, hospitals, clinics and other healthcare provider locations (Source: Urch Publishing, July 2009). Visiongain's Anti-Counterfeiting Americas conference will provide valuable insights, into the latest issues and track and trace packaging technologies shaping the fields of security and supply chain management, with leading experts presenting the best-practices on tackling pharmaceutical counterfeiting and fraud, improving the integrity of distribution channels and relationships between key parties.

Biobanking Americas

info@visiongain.com (visiongain) — Tue, 09 Nov 2010 00:00:00 GMT

9th - 11th November 2010, Boston, USA
An estimated $1bn has been invested in the biobanking industry within the last ten years. At least 179 biobanks with 345,000 donors exist in the US, most of which were established in the last 10 years. TIME Magazine highlighted biobanking as one of "10 Ideas Changing the World Right Now." Biobanking is rapidly growing and thriving to change approaches to target-finding, drug development and patient treatment. It is being viewed as a key driver for next generation biomarker and drug discovery.

4th Annual Stability Testing

info@visiongain.com (visiongain) — Mon, 22 Nov 2010 00:00:00 GMT

22nd - 23rd November 2010, London, UK
Failing to conduct a proper stability testing can be very time consuming and costly for companies, and damaging to their reputation. The cost of taking NCE through the development stages can range anywhere between $800 million to $1.2 billion (source: Springer, 2009). It is therefore, important for companies to understand key factors affecting the stability profile of a potential product, and carry out an effective stability program.

Dermatological Advances 2010

info@visiongain.com (visiongain) — Wed, 01 Dec 2010 00:00:00 GMT

1st - 2nd December 2010, London, UK
The dermatological market remains highly competitive, with increasing investment by big pharmaceutical and specialty biotech firms. With current worldwide revenues of $20bn, the area remains arguably the most lucrative of all pharmaceutical sectors today. New treatments and increasing disease prevalence will drive significant area expansion over the next 15 years.

4th Annual Contract Manufacturing Conference

info@visiongain.com (visiongain) — Mon, 13 Dec 2010 00:00:00 GMT

13th - 14th December 2010, London, UK
The global demand for contract manufacturing services and affordable outsourcing solutions is increasingly driving the pharmaceutical companies to upgrade their technology and manufacturing capacity. In recent times, investments in implementation of PAT and QbD applications, to ensure high quality and timely supply, have become the prime focus of pharmaceutical and biotech industry. As the competition from off-patent products, in-licensing and mergers and acquisitions grows, Asia is expected to become one of the largest cost-effective outsourcing markets in the next five years.

4th Annual Recombinant Antibodies

info@visiongain.com (visiongain) — Wed, 19 Jan 2011 00:00:00 GMT

19th - 21st January 2011, London, UK
Antibodies remain amongst the most exciting protein therapeutics today, with 22 in use and 26 candidates in Phase III trials. With ongoing growth of 12-15%, the global antibody market will reach $70bn by 2013, as new approvals and a growing world population drive consumer demand.

Amorphous Pharmaceutical Materials

info@visiongain.com (visiongain) — Mon, 24 Jan 2011 00:00:00 GMT

24th - 25th January 2011, London, UK
Due to the continuous increase in the number of insoluble developmental drug molecules and growing regulatory scrutiny over pharmaceutical solids, the amorphous pharmaceutical materials have gained importance in the last few years. With the help of interactive discussions, leading presentations, participants will gain a comprehensive outlook of the current market trends, and discover the latest technological developments.

5th Annual Smoking Cessation

info@visiongain.com (visiongain) — Thu, 27 Jan 2011 00:00:00 GMT

27th - 28th January 2011, London, UK
Smoking remains one of the biggest health threats in the world, causing 5.4 million deaths worldwide and 100,000 deaths in the UK each year. With governments and health organisations constantly warning of dangers of smoking, there's never been more pressure on smokers to quit. Figures suggest that around 50% of quit attempts involve the use of smoking cessation aids, usually in the form of nicotine replacement therapy (NRT), purchased over the counter. Most unaided attempts are often not very successful.

6th Annual Drug Delivery Systems

info@visiongain.com (visiongain) — Tue, 01 Feb 2011 00:00:00 GMT

1st - 2nd February 2011, London, UK
Shrinking global capital markets, new healthcare policies, ageing populations, the growth of emerging economies, technological advances and the advent of regenerative and biological medicines are just some of the factors expected to shape the future drug delivery device market. (Source: Cambridge Consultants UK, September 2009)

2nd Annual Diabetes and Diabetic Retinopathy

info@visiongain.com (visiongain) — Mon, 07 Feb 2011 00:00:00 GMT

7th - 8th February 2011, London, UK
Diabetes is becoming an epidemic and is expected to reach $86.9 billion by 2025; world health organisation predicts that 4.4% of the world population will have diabetes by 2030. Of the 246 million people with diabetes about third have signs of diabetic retinopathy and about third of these might have vision-threatening retinopathy defined as severe retinopathy or macular oedema.

Vaccine Research & Innovation 2011

info@visiongain.com (visiongain) — Thu, 10 Feb 2011 00:00:00 GMT

10th - 11th February 2011, London, UK
Increasing use of novel technologies has boosted the vaccines industry worldwide. Recent technological breakthroughs in vaccine research, manufacturing and delivery, promise a bright future for the new generation of vaccines, particularly for chronic conditions such as cancer, auto-immune diseases and nicotine addiction.

Paediatric Drug Development

info@visiongain.com (visiongain) — Wed, 23 Feb 2011 00:00:00 GMT

23rd - 25th February 2011, London, UK
Children make up a large percentage of the patient population, yet they are regularly treated with medicines which are not researched or licensed for their age group. In recent years, new EU regulations in the field of paediatrics have generated significant increase in interest and resources dedicated to paediatric drug development. There is now a worldwide awareness that drug treatment of children differs in its scientific context to the regulatory and scientific framework that define drugs for adults.

5th Lyophilization Conference

info@visiongain.com (visiongain) — Wed, 23 Feb 2011 00:00:00 GMT

23rd - 25th February 2011, TBC, USA
With over 130 products on the market worth $50bn, biologicals and biopharmaceuticals remain the fastest growing segment amongst novel pharmaceutical entities today. Mirroring this trend, the market for lyophilising these compounds, currently approaching 200 million units, is set to continue its year-on-year double digit growth.

Biosimilars and Follow-On Biologics Americas

info@visiongain.com (visiongain) — Mon, 28 Feb 2011 00:00:00 GMT

28th February - 2nd March 2011, USA
In 2008, the total revenues of biologic drugs were valued at $122.96bn, counting for 15% of the total pharmaceutical market (Visiongain, 2009), making it one of fastest growing markets. In March 2010, the US Congress passed the much awaited legislation which would give the US FDA the authority to approve generic versions of the innovator biologic drug. Branded drug makers were given 12-year exclusivity before the generic version can be developed. Interest is likely to continue as patents on almost all available biologic drugs, either expired, or are due expire during 2009-2024.

6th Annual Pharmacovigilance

info@visiongain.com (visiongain) — Wed, 16 Mar 2011 00:00:00 GMT

16th - 17th March 2011, London, UK
Drug safety has long been an issue however the concern has risen again in recent years following high profile scares. In 2009, FDA reported more than 1,742 recall in comparison to 426 in 2008 and fast pace of drug recalls seems to be continuing in 2010 totalled 296 from January through June of this year.

2nd Annual Pricing & Reimbursement for Medical Devices

info@visiongain.com (visiongain) — Tue, 22 Mar 2011 00:00:00 GMT

22nd - 23rd March 2011, London, UK
The global economic crisis and rising healthcare costs are making pricing and reimbursement for medical devices an increasingly delicate balancing act. European countries, whose healthcare is mostly state-funded, are finding it ever more challenging to meet the needs of a growing elderly population. In parallel, new healthcare legislation in the USA, will see payers, employers, and group purchasing organisations reigning in health care costs. Hospitals will negotiate harder for better prices on medical devices as DRG payments for procedures continue to shrink and their own costs continue to rise.